Healthcare Sector — Q1 FY24 Earnings Overview
4 companies reported. 2 bullish, 2 neutral, 0 bearish.
Company Results
| Company | Revenue | YoY | Margin | Sentiment |
|---|---|---|---|---|
| Sunpharma | ₹11,785 Cr | +10.7% | 27.8% | neutral medium |
| Cipla | ₹6,329 Cr | +18% | 23.6% | bullish high |
| Apollohosp | ₹4,418 Cr | +16% | 12.0% | bullish medium |
| Sbilife | — | — | — | neutral medium |
Key sector risks this quarter
Supplies from Mohali have not resumed; residual inventory sales are declining. Market share loss may be permanent depending on competition and contracts.
Cipla · highCipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.
Cipla · highCipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.
Sunpharma · mediumIndia market share fell to 8.33% from 8.5% due to NLEM price cuts and sitagliptin patent expiry. Recovery timeline uncertain.
Sunpharma · mediumManagement provided no update on the Taro minority buyout beyond forming a special committee. Strategic benefits remain unclear.